CRNA Perioperative Assessment for GLP-1s CRNAs must ask their usual screening questions, as well as inquire about the patients use of GLP-1s, their dosage, and the duration of their treatment, among other details
Around 21.8% of people using salbutamol are living with obesity, with higher rates in mild to moderate cases
Metabolomics and isotope tracing
GLP-1 Weight Loss Drugs: The Untold Story Risks, Rebound, and the Role of Nutritional Therapy The rise in popularity of GLP-1 agonist weight loss drugs like Mounjaro (tirzepatide) and Ozempic (semaglutide) is undeniable
The side effects appear consistent with the incretin class (GI issues), but as physicians, managing patient titration and comfort will be critical if this comes to market
Pflug, J